Sacrix’s patented screw design with cortical threads adjacent to cancellous threads plus fusion channels
“Sacrix has noticed that many companies have now copied our design of the cortical and cancellous threads with a channel and 3D porous structure which are covered by the Patent US 11,129,655” says Professor Dr. Kingsley R Chin.
MALDEN, Mass. (PRWEB)
July 19, 2022
Sacrix’s sacrofuse has a unique design and technique and was issued a United States patent on September 28th, 2021. Sacrix highlights two important claims.
Key Patented Claims
We received patent protection on our design having cortical threads adjacent to cancellous threads plus fusion channels. This is a significant claim since the anatomy and trajectory require differential threads and self-harvesting bone channels. We note companies copying these features.
1. A bone fusing implant device comprising: an elongated body extending along a longitudinal direction; wherein the elongated body comprises a first segment having an outer surface with cortical threads, a second segment having an outer surface with cancellous threads, a top segment and a bottom segment; wherein the first segment is adjacent to the second segment along the longitudinal direction and is configured to engage a cortical bone with the cortical threads and the second segment is configured to engage a cancellous bone with the cancellous threads; wherein the elongated body comprises one or more elongated fusing gutters extending along the longitudinal direction on an outer surface of the elongated body covering the first and second segments, a central opening extending along the longitudinal direction through the elongated body’s center and one or more through openings that extend horizontally and intersect with the one or more fusing gutters; wherein the cortical threads are more closely spaced than the cancellous threads.
This is an important claim to protect our 3D porous structure design.
2. The device of claim 1, wherein the elongated fusing gutters comprise a trabecular lattice structure and do not cut through the cortical threads and the cancellous threads.
“We focus on innovating surgical techniques, instrumentation and ultimately the implanted device. Our granted patent is a testament to the innovation we intend to enforce and maintain our ability to improve patient care” said Vito Lore, VP of Innovation
“Sacrix has noticed that many companies have now copied our design of the cortical and cancellous threads with a channel and 3D porous structure which are covered by the Patent US 11,129,655,” said Co-Inventor Dr Kingsley R. Chin, a Professor and Board-Certified Orthopedic Spine Surgeon and interim-acting CEO of Sacrix LLC. “This is a serious matter that has our focused attention”
We believe innovation is better for patient care and copying sets back the industry. Our competitors should focus on innovating to push the field forward. The Sacrix percutaneous lateral-oblique technique uses two steps under 100% fluoroscopy, no open incision, and is a perfect complement to the screw design for sacroiliac joint fixation. There is no need for drilling or tapping, even in patients with advanced osteoporosis and no device-related failure with clinical use so far. The 3D porous thread design and channel for fusion are significant advances in sacroiliac joint fixation over competitive products such as SI-Bone TTI and other partially threaded screws in the market.
About Sacrix LLC
Sacrix LLC is a KICVentures Group portfolio company focused on revolutionary percutaneous fluoroscopic lateral-oblique sacroiliac joint fusion technologies for the treatment of sacroiliac dysfunction and sacroiliitis. Sacrix developed its patented Sacrofuse threaded implant to be inserted percutaneously and received FDA clearance in 2015. The Gen1 Sacrofuse implant was compared head-to-head with market leader SI bone (SIBN) and found to have a 400% increase in pull-out strength. Sacrix has trained over 165 interventional pain physicians to perform its revolutionary percutaneous lateral-oblique sacroiliac joint fusion technique safely and effectively through a 1.5 cm incision minimally invasively in outpatient ambulatory surgery centers.
http://www.MySacrix.com
About KICVentures Group
Founded in 2000 makes us the most experienced healthcare investment holding company with the largest portfolio of medical device technologies focused on solutions for less invasive outpatient spine surgery. Our investment strategy is to acquire or invent disruptive technologies using our own capital or partner with private individual investors. This allows us the freedom to make quick and nimble decisions such as when we acquired AxioMed Viscoelastic Disc Technologies while other firms invested in ball-and-socket articulating spacers.
http://www.KICVentures.com
Share article on social media or email: